Presentation is loading. Please wait.

Presentation is loading. Please wait.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

Published byLynne Howard Modified over 5 years ago

Similar presentations

Presentation on theme: "Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model."— Presentation transcript:

1 Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo.
Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. BT-474 (A) and MDA-MB-453 (B) breast cancer cells were implanted subcutaneously into athymic nude mice. Intravenous injection of either saline (control) or HER2-lytic peptide (3 mg/kg) is indicated by the arrows. Data are expressed as mean ± SD (n = 6 animals in each group). C, histological examination after treatment with HER2-lytic peptide. Images (magnification, ×400) of liver, kidney, and spleen from mice after treatment with saline (control) or HER2-lytic peptide (3 mg/kg) 9 times were obtained by staining with hematoxylin and eosin. Megumi Kawamoto et al. Mol Cancer Ther 2013;12: ©2013 by American Association for Cancer Research

Download ppt "Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model."

Similar presentations

Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in.

Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in.
Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.
AZD9291 inhibits EGFR phosphorylation and downstream signaling in murine models of EGFRT790M-resistant lung cancer. AZD9291 inhibits EGFR phosphorylation.

AZD9291 inhibits EGFR phosphorylation and downstream signaling in murine models of EGFRT790M-resistant lung cancer. AZD9291 inhibits EGFR phosphorylation.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Antitumor activity of BAY in patient-derived tumor models.

Antitumor activity of BAY in patient-derived tumor models.
Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.
Effects of SC144 on in vivo ovarian tumor.

Effects of SC144 on in vivo ovarian tumor.
Validation of St6GalNAc2 as a metastasis suppressor gene.

Validation of St6GalNAc2 as a metastasis suppressor gene.
HER2 mutants V777L, G309A, D769H formed tumors more rapidly than HER2 WT. A, a total of 0.5 × 106 cells of NIH3T3 expressing either HER2 WT or mutant were.

HER2 mutants V777L, G309A, D769H formed tumors more rapidly than HER2 WT. A, a total of 0.5 × 106 cells of NIH3T3 expressing either HER2 WT or mutant were.
Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
Volume 18, Issue 2, Pages (February 2010)

Volume 18, Issue 2, Pages (February 2010)
Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.
Antitumor effects of FF and gemcitabine on two pancreatic PDX models.

Antitumor effects of FF and gemcitabine on two pancreatic PDX models.
Molecular Therapy - Nucleic Acids

Molecular Therapy - Nucleic Acids
Increase in beige/brown adipocyte characteristics in the xenografts from additional breast cancer cell lines. Increase in beige/brown adipocyte characteristics.

Increase in beige/brown adipocyte characteristics in the xenografts from additional breast cancer cell lines. Increase in beige/brown adipocyte characteristics.
Bioluminescence imaging facilitates detection of tumor growth and metastasis in mouse orthotopic xenograft model. Bioluminescence imaging facilitates detection.

Bioluminescence imaging facilitates detection of tumor growth and metastasis in mouse orthotopic xenograft model. Bioluminescence imaging facilitates detection.
In vivo efficacy of Olaparib in PTEN deficient xenografts.

In vivo efficacy of Olaparib in PTEN deficient xenografts.
Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies in athymic nude mice bearing the s.c. Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies.

Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies in athymic nude mice bearing the s.c. Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies.
Activity of MAC-321 (i. v. and p. o

Activity of MAC-321 (i. v. and p. o

Similar presentations

Ads by Google